Neurocrine Biosciences (NBIX) Profit After Tax Growth (1y) (2011 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Profit After Tax Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn | -0.05% |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn | -130.19% |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn | -19.06% |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | -108.47% |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn | -90.18% |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 44.59% |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn | 7.59% |
| 10 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 34.32% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 34.32% |
| Mar 31, 2026 | 1,682.88% |
| Dec 31, 2025 | 60.67% |
| Sep 30, 2025 | 48.24% |
| Jun 30, 2025 | 70.77% |
| Mar 31, 2025 | -74.42% |
| Dec 31, 2024 | -38.87% |
| Sep 30, 2024 | 70.64% |
| Jun 30, 2024 | -33.06% |
| Mar 31, 2024 | 156.66% |
| Dec 31, 2023 | 75.73% |
| Sep 30, 2023 | 21.31% |
| Jun 30, 2023 | 590.40% |
| Mar 31, 2023 | -651.08% |
| Dec 31, 2022 | 1,319.18% |
| Sep 30, 2022 | 204.44% |
| Jun 30, 2022 | -146.81% |
| Mar 31, 2022 | -56.70% |
| Dec 31, 2021 | -102.10% |
| Sep 30, 2021 | 138.14% |